Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors

Journal of Medicinal Chemistry

Volumn 58, Issue 4, 2015, Pages 1846-1861

  Yin, Yan ^a,f   Zheng, Ke ^a   Eid, Nibal ^b,d   Howard, Shannon ^b,d   Jeong, Ji Hak ^e   Yi, Fei ^g   Guo, Jia ^g   Park, Chul Min ^a,h   Bibian, Mathieu ^a   Wu, Weilin ^e   Hernandez, Pamela ^b,d   Park, Hajeung ^c   Wu, Yuntao ^g   Luo, Jun Li ^e   Lograsso, Philip V ^b,d   Feng, Yangbo ^a  

^a Medicinal Chemistry   (United States)

^b Discovery Biology   (United States)

^c Translational Research Institute   (United States)

^d Department of Molecular Therapeutics ^*  (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f SHANGHAI INSTITUTE OF TECHNOLOGY   (China)

^g GEORGE MASON UNIVERSITY   (United States)

^h Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 FLUOROPHENYL) 1 (2 HYDROXYETHYL) 3 [4 (5 METHYL 7H PYRROLO[ 2,3 D]PYRIMIDIN 4 YL)PHENYL]UREA; 1 (2 HYDROXYETHYL) 3 [4 (5 METHYL 7H PYRROLO[2,3 D] PYRIMIDIN 4 YL)PHENYL] 1 PHENYLUREA; 1 (2 METHOXYPHENYL) 3 [4 (5 METHYL 7H PYRROLO[2,3 D] PYRIMIDIN 4 YL)PHENYL]UREA; 1 (3 FLUOROPHENYL) 3 [4 (5 METHYL 7H PYRROLO[2,3 D] PYRIMIDIN 4 YL)PHENYL]UREA; 1 (3 METHOXYPHENYL) 3 [4 (5 METHYL 7H PYRROLO[2,3 D] PYRIMIDIN 4 YL)PHENYL]UREA; 1 (4 CHLOROPHENYL) 3 [4 (5,6 DIMETHYL 7H PYRROLO[2,3 D] PYRIMIDIN 4 YL) 2 FLUOROPHENYL] 1 [2 (DIMETHYLAMINO)ETHYL] UREA; 1 (4 METHOXYPHENYL) 3 [4 (5 METHYL 7H PYRROLO[2,3 D] PYRIMIDIN 4 YL)PHENYL]UREA; 1 [4 (5 METHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL)PHENYL] 3 PHENYLUREA; 1 [4 (5 METHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL)PHENYL] 3 PYRIDIN 2 YLUREA; 1 [4 (5 METHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL)PHENYL] 3 THIAZOL 2 YLUREA; 3 (4 METHOXYPHENYL) 1 METHYL 1 [4 (5 METHYL 7H PYRROLO [2,3 D]PYRIMIDIN 4 YL)PHENYL]UREA; 3 (4 METHOXYPHENYL) 1 [4 (5 METHYL 7H PYRROLO[2,3 D] PYRIMIDIN 4 YL)PHENYL] 1 [2 (PIPERIDIN 1 YL)ETHYL]UREA; 3 (4 METHOXYPHENYL) 1 [4 (5 METHYL 7H PYRROLO[2,3 D] PYRIMIDIN 4 YL)PHENYL] 1 [2 (PYRROLIDIN 1 YL)ETHYL]UREA; 3 [3 [2 FLUORO 4 (5 METHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) PHENYL]UREIDO] N ISOPROPYLBENZAMIDE; 3 [3 [2 [2 (DIMETHYLAMINO)ETHOXY] 4 (5 METHYL 7H PYRROLO [2,3 D]PYRIMIDIN 4 YL)PHENYL]UREIDO] N ISOPROPYLBENZAMIDE; 3 [3 [4 (1H PYRAZOL 4 YL)PHENYL]UREIDO] N ISOPROPYLBENZAMIDE; 3 [3 [4 (2 AMINOPYRIMIDIN 4 YL)PHENYL]UREIDO] N ISOPROPYLBENZAMIDE; 3 [3 [4 (5,6 DIMETHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) PHENYL]UREIDO] N ISOPROPYLBENZAMIDE; 3 [3 [4 (7H PYRROLO[2,3 D]PYRIMIDIN 4 YL)PHENYL]UREIDO] N ISOPROPYLBENZAMIDE; 3 [4 (5 METHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL)PHENYL] 1 PHENYL 1 [2 (PYRROLIDIN 1 YL)ETHYL]UREA; 4 [3 [4 (7 ETHYL 8 OXO 8,9 DIHYDRO 7H PURIN 6 YL)PHENYL] UREIDO] N ISOPROPYLBENZAMIDE; N ISOPROPYL 3 [3 [4 (5 METHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL)PHENYL]UREIDO]BENZAMIDE; N ISOPROPYL 3 [3 [4 (6 METHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL)PHENYL]UREIDO]BENZAMIDE; N ISOPROPYL 3 [3 [4 (PYRIDIN 4 YL)PHENYL]UREIDO]BENZAMIDE; N ISOPROPYL 4 [3 [4 (1H PYRROLO[2,3 B]PYRIDIN 4 YL)PHENYL] UREIDO]BENZAMIDE; N ISOPROPYL 4 [3 [4 (9H PURIN 6 YL)PHENYL]UREIDO]BENZAMIDE; N SOPROPYL 3 [3 [4 (5 METHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 2 (TRIFLUOROMETHYL)PHENYL]UREIDO]BENZAMIDE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE; LIM KINASE; PROTEIN KINASE INHIBITOR; UREA;

ALKYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CARCINOMA CELL LINE; CELL ACTIVITY; CELL INVASION; CELL MIGRATION; CRYSTAL STRUCTURE; DEMETHYLATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONFORMATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DOCKING; NONHUMAN; PROSTATE CARCINOMA; PROTEIN PHOSPHORYLATION; RAT; STRUCTURE ACTIVITY RELATION; VOLUME OF DISTRIBUTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; ENZYMOLOGY; METABOLISM; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIM KINASES; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 84923911728     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501680m     Document Type: Article

References (66)

1. Bernard, O.; Ganiatsas, S.; Kannourakis, G.; Dringen, R. Kiz-1, a protein with LIM zinc finger and kinase domains, is expressed mainly in neurons Cell Growth Differ. 1994, 5, 1159-1171
2. Stanyon, C. A.; Bernard, O. LIM-kinase1 Int. J. Biochem. Cell Biol. 1999, 31, 389-394
3. Mizuno, K.; Okana, I.; Ohashi, K.; Nunoue, K.; Kuma, K.; Miyata, T.; Nakamura, T. Identification of a human cDNA encoding a novel protein kinase with two repeats of the LIM/double Zinc finger motif Oncogene 1994, 9, 1605-1612
4. Osada, H.; Hasada, K.; Inazawa, J.; Uchida, K.; Ueda, R.; Takahashi, T.; Takahashi, T. Subcellular localization and protein interaction of the human LIMK2 gene expressing alternative transcripts with tissue-specific regulation Biochem. Biophys. Res. Commun. 1996, 229, 582-589
5. Bernard, O. Lim kinases, regulators of actin dynamics Int. J. Biochem. Cell Biol. 2007, 39, 1071-1076
6. Acevedo, K.; Moussi, N.; Li, R.; Soo, P.; Bernard, O. LIM kinase 2 is widely expressed in all tissues J. Histochem. Cytochem. 2006, 54, 487-501
7. Scott, R. W.; Olson, M. F. LIM kinases: function, regulation and association with human disease J. Mol. Med. (Berlin) 2007, 85, 555-568
8. Arber, S.; Barbayannis, F. A.; Hanser, H.; Schneider, C.; Stanyon, C. A.; Bernard, O.; Caroni, P. Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase Nature 1998, 393, 805-809
9. Edwards, D. C.; Sanders, L. C.; Bokoch, G. M.; Gill, B. N. Activation of LIM-kinased by Pak1 couples Rac/Cdc42 GTPase signaling to actin cytoskeletal dynamics Nat. Cell Biol. 1999, 1, 253-259
10. Maekawa, M.; Ishizaki, T.; Boku, S.; Watanabe, N.; Fujita, A.; Iwamatsu, A.; Obinata, T.; Ohashi, K.; Mizuno, K.; Narumiya, S. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase Science 1999, 285, 895-898
11. Vlachos, P.; Joseph, B. The Cdk inhibitor p57(Kip2) controls LIM-kinase 1 activity and regulates actin cytoskeleton dynamics Oncogene 2009, 28, 4175-4188
12. Thirone, A. C.; Speight, P.; Zulys, M.; Rotstein, O. D.; Szaszi, K.; Pedersen, S. F.; Kapus, A. Hyperosmotic stress induces Rho/Rho kinase/LIM kinase-mediated cofilin phosphorylation in tubular cells: key role in the osmotically triggered F-actin response Am. J. Physiol.: Cell Physiol. 2009, 296, C463-475
13. Hoogenraad, C. C.; Akhmanova, A.; Galjart, N.; De Zeeuw, C. I. LIMK1 and CLIP-115: linking cytoskeletal defects to Williams syndrome BioEssays 2004, 26, 141-150
14. Piccioli, Z. D.; Littleton, J. T. Retrograde BMP signaling modulates rapid activity-dependent synaptic growth via presynaptic LIM kinase regulation of cofilin J. Neurosci. 2014, 34, 4371-4381
15. Heredia, L.; Helguera, P.; de Olmos, S.; kedikian, G.; Sola Vigo, F.; LaFerla, F. Phosphorylation of actin-depolymerizing factor/cofilin by Lim-kinase mediates amylolid beta-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimers disease J. Neurosci. 2006, 26, 6533-6542
16. Honma, M.; Benitah, S. A.; Watt, F. M. Role of LIM kinases in normal and psoriatic human epidermis Mol. Biol. Cell 2006, 17, 1888-1896
17. Bongalon, S.; Dai, Y. P.; Singer, C. A.; Yamboliev, I. A. PDGF and IL-1beta upregulate cofilin and LIMK2 in canine cultured pulmonary artery smooth muscle cells J. Vasc. Res. 2004, 41, 412-421
18. Dai, Y. P.; Bongalon, S.; Tian, H.; Parks, S. D.; Mutafova-Yambolieva, V. N.; Yamboliev, I. A. Upregulation of profilin, cofilin-2 and LIMK2 in cultured pulmonary artery smooth muscle cells and in pulmonary arteries of monocrotaline-treated rats Vascul. Pharmacol. 2006, 44, 275-282
19. Akagawa, H.; Tajima, A.; Sakamoto, Y.; Krischek, B.; Yoneyama, T.; Kasuya, H.; Onda, H.; Hori, T.; Kubota, M.; Machida, T.; Saeki, N.; Hata, A.; Hashiguchi, K.; Kimura, E.; Kim, C. J.; Yang, T. K.; Lee, J. Y.; Kimm, K.; Inoue, I. A haplotype spanning two genes, ELN and LIMK1, decreases their transcripts and confers susceptibility to intracranial aneurysms Hum. Mol. Genet. 2006, 15, 1722-1734
20. Harrison, B. A.; Whitlock, N. A.; Voronkov, M. V.; Almstead, Z. Y.; Gu, K. J.; Mabon, R.; Gardyan, M.; Hamman, B. D.; Allen, J.; Gopinathan, S.; McKnight, B.; Crist, M.; Zhang, Y.; Liu, Y.; Courtney, L. F.; Key, B.; Zhou, J.; Patel, N.; Yates, P. W.; Liu, Q.; Wilson, A. G.; Kimball, S. D.; Crosson, C. E.; Rice, D. S.; Rawlins, D. B. Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma J. Med. Chem. 2009, 52, 6515-6518
21. Xu, X.; Guo, J.; Vorster, P.; Wu, Y. Involvement of LIM kinase 1 in actin polarization in human CD4 T cells Commun. Integr. Biol. 2012, 5, 381-383
22. Manetti, F. HIV-1 proteins join the family of LIM kinase partners. New roads open up for HIV-1 treatment Drug Discovery Today 2012, 17, 81-88
23. Vorster, P. J.; Guo, J.; Yoder, A.; Wang, W.; Zheng, Y.; Xu, X.; Yu, D.; Spear, M.; Wu, Y. LIM kinase 1 modulates cortical actin and CXCR4 cycling and is activated by HIV-1 to initiate viral infection J. Biol. Chem. 2011, 286, 12554-12564
24. Wen, X.; Ding, L.; Wang, J. J.; Qi, M.; Hammonds, J.; Chu, H.; Chen, X.; Hunter, E.; Spearman, P. ROCK1 and LIM kinase modulate retrovirus particle release and cell-cell transmission events J. Virol. 2014, 88, 6906-6921
25. Bagheri-Yarmand, R.; Mazumdar, A.; Sahin, A. A.; Kumar, R. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system Int. J. Cancer 2006, 118, 2703-2710
26. Davila, M.; Frost, A. R.; Grizzle, W. E.; Chakrabarti, R. LIM kinase 1 is essential for the invasive growth of prostate epithelial cells: implications in prostate cancer J. Biol. Chem. 2003, 278, 36868-36875
27. Davila, M.; Jhala, D.; Ghosh, D.; Grizzle, W. E.; Chakrabarti, R. Expression of LIM kinase 1 is associated with reversible G1/S phase arrest, chromosomal instability and prostate cancer Mol. Cancer 2007, 6, 40
28. Manetti, F. LIM kinases are attractive targets with many macromolecular partners and only a few small molecule regulators Med. Res. Rev. 2012, 32, 968-998
29. Suyama, E.; Wadhwa, R.; Kawasaki, H.; Yaguchi, T.; Kaul, S. C.; Nakajima, M.; Taira, K. LIM kinase-2 targeting as a possible anti-metastasis therapy J. Gene Med. 2004, 6, 357-363
30. Manetti, F. Recent findings confirm LIM domain kinases as emerging target candidates for cancer therapy Curr. Cancer Drug Targets 2012, 12, 543-560
31. Ohashi, K.; Sampei, K.; Nakagawa, M.; Uchiumi, N.; Amanuma, T.; Aiba, S.; Oikawa, M.; Mizuno, K. Damnacanthal, an effective inhibitor of LIM-kinase, inhibits cell migration and invasion Mol. Biol. Cell 2014, 25, 828-840
32. Park, J. B.; Agnihotri, S.; Golbourn, B.; Bertrand, K. C.; Luck, A.; Sabha, N.; Smith, C. A.; Byron, S.; Zadeh, G.; Croul, S.; Berens, M.; Rutka, J. T. Transcriptional profiling of GBM invasion genes identifies effective inhibitors of the LIM kinase-Cofilin pathway Oncotarget 2014, 5, 9382-9395
33. Rak, R.; Kloog, Y. Targeting LIM kinase in cancer and neurofibromatosis Cell Cycle 2014, 13, 1360-1361
34. Mashiach-Farkash, E.; Rak, R.; Elad-Sfadia, G.; Haklai, R.; Carmeli, S.; Kloog, Y.; Wolfson, H. J. Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton Oncotarget 2012, 3, 629-639
35. Iyengar, S.; Hildreth, J. E.; Schwartz, D. H. Actin-dependent receptor colocalization required for human immunodeficiency virus entry into host cells J. Virol. 1998, 72, 5251-5255
36. Ross-Macdonald, P.; de Silva, H.; Guo, Q.; Xiao, H.; Hung, C. Y.; Penhallow, B.; Markwalder, J.; He, L.; Attar, R. M.; Lin, T. A.; Seitz, S.; Tilford, C.; Wardwell-Swanson, J.; Jackson, D. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors Mol. Cancer Ther. 2008, 7, 3490-3498
37. He, L.; Seitz, S. P.; Trainor, G. L.; Tortolani, D.; Vaccaro, W.; Poss, M.; Tarby, C. M.; Tokarski, J. S.; Penhallow, B.; Hung, C. Y.; Attar, R.; Lin, T. A. Modulation of cofilin phosphorylation by inhibition of the Lim family kinases Bioorg. Med. Chem. Lett. 2012, 22, 5995-5998
38. Sleebs, B. E.; Nikolakopoulos, G.; Street, I. P.; Falk, H.; Baell, J. B. Identification of 5,6-substituted 4-aminothieno[2,3- d ]pyrimidines as LIMK1 inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 5992-5994
39. Sleebs, B. E.; Ganame, D.; Levit, A.; Street, I. P.; Gregg, A.; Falkabc, H.; Baell, J. B. Development of substituted 7-phenyl-4-aminobenzothieno[3,2- d ]pyrimidines as potent LIMK1 inhibitors Med. Chem. Commun. 2011, 2, 982-986
40. Goodwin, N. C.; Cianchetta, G.; Burgoon, H. A.; Healy, J.; Mabon, R.; Strobel, E. D.; Allen, J.; Wang, S.; Hamman, B. D.; Rawlins, D. B. Discovery of a type III inhibitor of LIM kinase 2 that binds in a DFG-out conformation ACS Med. Chem. Lett. 2015, 6, 53-57
41. Yin, Y.; Cameron, M. D.; Lin, L.; Khan, S.; Schröter, T.; Grant, W.; Pocas, J.; Chen, Y. T.; Schürer, S.; Pachori, A.; LoGrasso, P.; Feng, Y. Discovery of highly potent and selective urea-based ROCK inhibitors and their effects on intraocular pressure in rats ACS Med. Chem. Lett. 2010, 1, 175-179
42. Yin, Y.; Lin, L.; Ruiz, C.; Khan, S.; Cameron, M. D.; Grant, W.; Pocas, J.; Eid, N.; Park, H.; Schroter, T.; Lograsso, P. V.; Feng, Y. Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors J. Med. Chem. 2013, 56, 3568-3581
43. Morita, Y.; Ishigaki, T.; Kawamura, K.; Iseki, K. Short and Practical Synthesis of N',N'-disubstituted N-aryl-1,2-ethylenediamines by a decarboxylative ring-opening reaction under nucleophilic conditions Synthesis 2007, 16, 2517-2523
44. Goodacre, C. J.; Bromidge, S. M.; Clapham, D.; King, F. D.; Lovell, P. J.; Allen, M.; Campbell, L. P.; Holland, V.; Riley, G. J.; Starr, K. R.; Trail, B. K.; Wood, M. D. A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists Bioorg. Med. Chem. Lett. 2005, 15, 4989-4993
45. Beletskaya, I. P.; Bessmertnykh, A. G.; Guilard, R. Halo-substituted aminobenzenes prepared by Pd-catalyzed amination Synlett 1999, 9, 1459-1461
46. Feng, Y.; Yin, Y.; Weiser, A.; Griffin, E.; Cameron, M. D.; Lin, L.; Ruiz, C.; Schürer, S. C.; Inoue, T.; Rao, P. V.; Schröter, T.; LoGrasso, P. Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors J. Med. Chem. 2008, 51, 6642-6645
47. Schröter, T.; Griffin, E.; Weiser, A.; Feng, Y.; LoGrasso, P. Detection of myosin light chain phosphorylation-a cell-based assay for screening Rho-kinase inhibitors Biochem. Biophys. Res. Commun. 2008, 374, 356-360
48. Feng, Y.; Cameron, M. D.; Frackowiak, B.; Griffin, E.; Lin, L.; Ruiz, C.; Schroter, T.; LoGrasso, P. Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II Bioorg. Med. Chem. Lett. 2007, 17, 2355-2360
49. Feng, Y.; Chambers, J. W.; Iqbal, S.; Koenig, M.; Park, H.; Cherry, L.; Hernandez, P.; Figuera-Losada, M.; LoGrasso, P. V. A small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK kinases ACS Chem. Biol. 2013, 8, 1747-1754
50. Chen, Y. T.; Bannister, T. D.; Weiser, A.; Griffin, E.; Lin, L.; Ruiz, C.; Cameron, M. D.; Schürer, S.; Duckett, D.; Schröter, T.; LoGrasso, P.; Feng, Y. Chroman-3-amides as potent Rho kinase inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 6406-6409
51. Ahmed, T.; Shea, K.; Masters, J. R.; Jones, G. E.; Wells, C. M. A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF Cell. Signalling 2008, 20, 1320-1328
52. Yin, Y.; Lin, L.; Ruiz, C.; Cameron, M. D.; Pocas, J.; Wayne, G.; Schröter, T.; Chen, W.; Duckett, D.; Schürer, S. C.; LoGrasso, P.; Feng, Y. Benzothiazole as Rho-associated kinase (ROCK-II) inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 6686-6690
53. Fang, X.; Yin, Y.; Wang, B.; Yao, L.; Chen, Y. T.; Schröter, T.; Weiser, A.; Pocas, J.; Wayne, G.; Cameron, M. D.; Lin, L.; Ruiz, C.; Khan, S.; Schürer, S. C.; Pachori, A.; LoGrasso, P.; Feng, Y. Tetrahydroisoquinoline derivatives as potent and selective Rho kinase Inhibitors J. Med. Chem. 2010, 53, 5727-5737
54. Chowdhury, S.; Chen, Y. T.; Fang, X.; Grant, W.; Pocas, J.; Cameron, M. D.; Ruiz, C.; Lin, L.; Park, H.; Schröter, T.; Bannister, T. D.; LoGrasso, P. V.; Feng, Y. Amino acid derived quinazolines as Rock/PKA inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 1592-1599
55. Zheng, K.; Iqbal, S.; Hernandez, P.; Park, H.; LoGrasso, P.; Feng, Y. Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives J. Med. Chem. 2014, 57, 10013-10030
56. Zhou, P.; Zou, J. W.; Tian, F. F.; Shang, Z. C. Fluorine bonding-How does it work in protein-ligand interactions? J. Chem. Inf. Model. 2009, 49, 2344-2355
57. Prudent, R.; Vassal-Stermann, E.; Nguyen, C. H.; Pillet, C.; Martinez, A.; Prunier, C.; Barette, C.; Soleilhac, E.; Filhol, O.; Beghin, A.; Valdameri, G.; Honore, S.; Aci-Seche, S.; Grierson, D.; Antonipillai, J.; Li, R.; Di Pietro, A.; Dumontet, C.; Braguer, D.; Florent, J. C.; Knapp, S.; Bernard, O.; Lafanechere, L. Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth Cancer Res. 2012, 72, 4429-4439
58. Yoshioka, K.; Foletta, V.; Bernard, O.; Itoh, K. A role for LIM kinase in cancer invasion Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 7247-7252
59. Wu, Y.; Beddall, M. H.; Marsh, J. W. Rev-dependent lentiviral expression vector Retrovirology 2007, 4, 12
60. Wu, Y.; Beddall, M. H.; Marsh, J. W. Rev-dependent indicator T cell line Curr. HIV Res. 2007, 5, 394-402
61. Mishima, T.; Naotsuka, M.; Horita, Y.; Sato, M.; Ohashi, K.; Mizuno, K. LIM-kinase is critical for the mesenchymal-to-amoeboid cell morphological transition in 3D matrices Biochem. Biophys. Res. Commun. 2010, 392, 577-581
62. Horita, Y.; Ohashi, K.; Mukai, M.; Inoue, M.; Mizuno, K. Suppression of the invasive capacity of rat ascites hepatoma cells by knockdown of Slingshot or LIM kinase J. Biol. Chem. 2008, 283, 6013-6021
63. Alers, J. C.; Rochat, J.; Krijtenburg, P. J.; Hop, W. C.; Kranse, R.; Rosenberg, C.; Tanke, H. J.; Schroder, F. H.; van Dekken, H. Identification of genetic markers for prostatic cancer progression Lab. Invest. 2000, 80, 931-942
64. Yang, N.; Higuchi, O.; Ohashi, K.; Nagata, K.; Wada, A.; Kangawa, K.; Nishida, E.; Mizuno, K. Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization Nature 1998, 393, 809-812
65. Ying, H.; Biroc, S. L.; Li, W. W.; Alicke, B.; Xuan, J. A.; Pagila, R.; Ohashi, Y.; Okada, T.; Kamata, Y.; Dinter, H. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models Mol. Cancer Ther. 2006, 5, 2158-2164
66. Hopkins, A. M.; Pineda, A. A.; Winfree, L. M.; Brown, G. T.; Laukoetter, M. G.; Nusrat, A. Organized migration of epithelial cells requires control of adhesion and protrusion through Rho kinase effectors Am. J. Physiol.: Gastrointest. Liver Physiol. 2007, 292, G806-817